QSAR Studies of 2-Phenoxyacetamide Analogues, a Novel Class of Potent and Selective Monoamine Oxidase Inhibitors

Ashish Kumar Singh; Jyoti Patel; Nimisha Jain; Pradeep Kumar Singour

doi:10.24092/CRPS.2017.070402

Ashish Kumar Singh Computational and Synthetic Chemistry Division,Department of Pharmaceutical Chemistry, VNS Group of Institutions- Faculty of Pharmacy, Berkheda Nathu, Neelbud, Bhopal (M.P.) - 462044 India
Jyoti Patel Computational and Synthetic Chemistry Division,Department of Pharmaceutical Chemistry, VNS Group of Institutions- Faculty of Pharmacy, Berkheda Nathu, Neelbud, Bhopal (M.P.) - 462044 India
Nimisha Jain Computational and Synthetic Chemistry Division,Department of Pharmaceutical Chemistry, VNS Group of Institutions- Faculty of Pharmacy, Berkheda Nathu, Neelbud, Bhopal (M.P.) - 462044 India
Pradeep Kumar Singour Computational and Synthetic Chemistry Division,Department of Pharmaceutical Chemistry, VNS Group of Institutions- Faculty of Pharmacy, Berkheda Nathu, Neelbud, Bhopal (M.P.) - 462044 India

DOI https://doi.org/10.24092/CRPS.2017.070402

Abstract

The primary objective of this investigation was to develop a QSAR model for novel series of phenoxy acetamide derivatives as Monoamine Oxidase Inhibitors. The data series were taken from the reported work of Wei Shen et al., 2014. The selected series consists of total 20 compounds, divided into two sets training set having 18 compounds and test set with 2 compounds. All the structures of phenoxy acetamide derivatives were sketched using Chem Office 2001. QSAR models were obtained by using VALSTAT software. The best-developed model showed a good correlative and predictive ability having regression coefficient (r2) of 0.9033 and q2 is 0.8376. For MAO B inhibitor activity, MW has positively correlated. The positive correlation of MW indicates that bulky group or higher molecular weight compounds are important for better MAO enzymes inhibition activity. The negative correlation of HOMO indicated that electrophilic group may increase the activity. The BetaPol also negatively correlated indicated less polar group give more activity. Based on the developed QSAR model, it may be concluded that highest occupied molecular orbital (HOMO) energy, molecular weight and Beta Polarizability are to be considered while designing newer compounds, for their potential MAO inhibitory activity.

Keywords: Monoamine Oxidise inhibitors, Quantitative Structure Activity Relationship (QSAR), Phenoxyacetamide, MAO-B, Statistical Analysis

References

1. Tipton KF. Enzymology of monoamine oxidase. Cell Biochem Funct. 1986; 4: 79-87.
2. Kalgutkar AS, Castagnoli N Jr., Testa B. Selective inhibitors of monoamine oxidase (MAO-A and MAO-B) as probes of its catalytic site and mechanism. Med Res Rev. 1995; 15: 325-388.
3. Singh V, Argal A, Mishra V, Raghuvanshi R, Agnihotri S. Antimalarial Activity: A QSAR Modeling of NF54 Strain of Plasmodium falciparum by Physicochemical Descriptor Calculation. Int J Res Pharm Sci. 2011; 1: 101-124.
4. Youdim MB, Bakhle YS. Monoamine oxidase: isoforms and inhibitors in Parkinson´s disease and depressive illness. Br J Pharm. 2006; 147: S287-S296.
5. Edmondson DE, Mattevi A, Binda C, Li M, Hubalek F. Structure and mechanism of monoamine oxidase. Curr Med Chem. 2004; 11: 1983-1993.
6. Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006; 7: 295-309.
7. Liccione J, Azzaro AJ. Different roles for type A and type B monoamine oxidase in regulating synaptic dopamine at D-1 and D-2 receptors associated with adenosine-3’,5’-cyclic monophosphate (cyclic AMP) formation. Naunyn. Schmiedeberg’s. Arch Pharmacol. 1988; 337: 151-158.
8. Finberg JPM, Rabey JM. Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology. Front Pharmacol. 2016; 7: 340.
9. Bortolato M, Chen K, Shih JC. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev. 2008; 60: 1527-1533.
10. Geha RM, Chen K, Wouters J, Ooms F, Shih JC. Analysis of conserved active site residues in monoamine oxidase A and B and their three-dimensional molecular modeling. J Biol Chem. 2002; 277: 17209-17216.
11. Guay DR. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am J Geriatr Pharmacother. 2006; 4: 330-346.
12. Fernandez HH, Chen JJ. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. Clin Neuropharmacol. 2007; 30: 150-168.
13. Fiedorowicz JG, Swartz KL. The Role of Monoamine Oxidase Inhibitors in Current Psychiatric Practice. J Psychiatr Pract. 2004; 10: 239-248.
14. Nantasenamat C, Isarankura-Na-Ayudhya, C, Naenna T, Prachayasittiku V. A Practical Overview of Quantitative Structure-Activity Relationship. EXCLI J. 2009; 8: 74-88.
15. Ma J, Yoshimura M, Yamashita E, Nakagawa A, Ito A, Tsukihara T. Structure of rat monoamine oxidase A and its specific recognitions for substrates and inhibitors. J Mol Biol. 2004; 338:103-114.
16. Gnerre C, Catto M, Leonetti F, Weber P, Carrupt PA, Altomare C, Carotti A, Testa B. Inhibition of monoamine oxidases by functionalized coumarin derivatives: biological activities, QSARs, and 3D-QSARs. J Med Chem. 2000; 43: 4747-4758.
17. Vilar S, Ferino G, Quezada E, Santana L, Friedman C. Predicting Monoamine Oxidase Inhibitory Activity through Ligand-Based Models. Curr Top Med Chem. 2012; 12: 2258-2274.
18. Chapman AG, Hart GP. Anticonvulsant drug action and regional neurotransmitter amino acid changes. J Neural Transm. 1988; 72: 201-212.
19. Silverman RB, Nishimura K, Lu X. Mechanism of inactivation of monoamine oxidase-B by the anticonvulsant agent milacemide (2-(n-pentylamino)acetamide). J Am Chem Soc. 1993; 115: 4949-4954.
20. Shen W, Yu S, Zhang J, Jia W, Zhu Q. Synthesis and Biological Evaluation of 2-Phenoxyacetamide Analogues, a Novel Class of Potent and Selective Monoamine Oxidase Inhibitors. Molecules. 2014; 19: 18620-18631.
21. Pathak A, Singour PK, Srivastav AK, Gouda P, Kumar S, Goutam BK. Hansch Analysis of Novel Acetamide Derivatives as Highly Potent and specific MAO-A Inhibitor. Cent Nerv Syst Agents Med Chem. 2016; 16(2): 143-151.
22. Pathak A, Srivastav AK, Singour PK, Gouda P. Synthetic and Natural Monoamine Oxidase Inhibitors as Potential Lead Compounds for Effective Theerapeutics. Cent Nerv Syst Agents Med Chem. 2016; 16(2): 81-97.
23. CS Chem office, version 6.0, Cambridge Soft corporation, Software publisher Association,1730 M Street, NW, Suite 700, Washington DC, USA, 20036, 452-1600.
24. Gupta AK, Arokia BM, Khakhedikar SG. Valstat: validated program for Qualitative structure activity relationships studies. Indian J Pharm Sci. 2004; 66: 396-402.